Insulin-like Growth Factor 1, Chromogranin A and Prostate Specific Antigen Serum Levels in Prostate Cancer Patients and Controls

This publication has 21 references indexed in Scilit:

• Neuroendocrine Differentiation in Prostate Cancer: Implications for New Treatment Modalities
  Published by Elsevier ,2004
• Circulating Free Insulin-Like Growth Factor (IGF)-I , Total IGF-I, and IGF Binding Protein-3 Levels Do Not Predict the Future Risk to Develop Prostate Cancer: Results of a Case-Control Study Involving 201 Patients within a Population-Based Screening with a 4-Year Interval
  Journal of Clinical Endocrinology & Metabolism, 2004
• High Levels of Circulating Insulin-Like Growth Factor-I Increase Prostate Cancer Risk: A Prospective Study in a Population-Based Nonscreened Cohort
  Journal of Clinical Oncology, 2004
• Screen‐detected prostate cancer and the insulin‐like growth factor axis: Results of a population‐based case‐control study
  International Journal of Cancer, 2004
• Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: Predictive value of serum chromogranin A
  The Prostate, 2003
• Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma
  The Prostate, 2003
• Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor Binding Protein-3 for Prostate Cancer Detection in Patients Undergoing Prostate Biopsy
  Journal of Urology, 2002
• Insulin-Like Growth Factor I Is Not a Useful Marker of Prostate Cancer in Men with Elevated Levels of Prostate-Specific Antigen
  Journal of Clinical Endocrinology & Metabolism, 2000
• Serum insulin‐like growth factor‐1 is not a useful marker of prostate cancer
  BJU International, 1999
• Human prostate-specific antigen: structural and functional similarity with serine proteases.
  Proceedings of the National Academy of Sciences, 1986